Trials / Completed
CompletedNCT02572349
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Cyclerion Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IW-1701 | |
| DRUG | Matching Placebo |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-10-08
- Last updated
- 2019-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02572349. Inclusion in this directory is not an endorsement.